An observational study in Psoriasis Arthritis, sponsored by Royal United Hospitals Bath NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Psoriasis with a site in United Kingdom — 9 open to participants now, 16 under way, 9 of them phase 3. Psoriasis · United Kingdom.
Among the 157 studies in Psoriasis with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2026, is one of 21 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 155th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →9 of the 157 studies in Psoriasis with a site in United Kingdom are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United Kingdom, United States, Canada and 10 more countries
Ages 18+
Royal United Hospitals Bath NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Argentina and 22 more countries
Ages 40+
LEO Pharma · Sites in United Kingdom, United States, Canada and 2 more countries
Ages 18+
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 67 · Phase 4 13
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 250 across the 135 interventional studies, 412 across the 21 observational. Of the 137 that completed or were terminated, 77 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 157 have an industry lead sponsor. The 10 most frequent:
Royal United Hospitals Bath NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Royal United Hospitals Bath NHS Foundation Trust has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
3 of the studies in Psoriasis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846813University of EdinburghEvidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring | 2026-12-31 |
| NCT07417995Royal United Hospitals Bath NHS Foundation TrustA Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis | 2027-06 |
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 157 studies in Psoriasis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.
The main questions are:
Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.
Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.
Study Design and Objectives
STRIDE-PsA is a prospective, multicentre observational cohort study conducted within routine NHS rheumatology care. Approximately ten NHS sites will recruit adults with psoriatic arthritis (PsA) initiating a new biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD). Participants will be followed for 52 weeks with assessments at baseline and weeks 4, 12, 24, and 52. As this is a non-interventional study, treatment decisions and clinical management will remain at the discretion of the treating clinician.
The study aims to evaluate treatment effectiveness across different lines of advanced therapy and to investigate whether anti-drug antibodies (ADAs) or circulating drug levels are associated with clinical response. The underlying hypothesis is that patients may achieve comparable clinical improvement despite multiple prior therapy switches.
Study Procedures and Data Collection
Participants will be followed for 52 weeks with assessments aligned to routine NHS rheumatology care. Data collection will include clinical examinations, patient-reported outcome measures (PROMs), and blood sampling for ADA and drug level analysis.
At baseline, informed consent will be obtained and demographic and clinical history recorded. Participants will undergo routine clinical assessment to derive disease activity measures (including cDAPSA, BSA, and minimal disease activity status), complete validated PROMs (PSAID-9, HAQ-DI, PGADA), and provide routine NHS blood tests. An additional small research blood sample will be collected, where feasible alongside routine bloods.
Follow-up assessments will occur at approximately Weeks 4, 12, 24, and 52. PROMs will be collected at each follow-up time point, with repeat clinical examination and a second research blood sample at Week 12 during routine care visits. Information on suspected treatment-related adverse events identified during routine clinical review will be recorded throughout follow-up.
All procedures are designed to align with standard NHS appointments to minimise additional participant burden, and visit windows are permitted to allow flexibility in scheduling.
Recruitment and Follow-up
Potential participants will be identified during routine rheumatology appointments by the direct care team and provided with study information. Written informed consent will be obtained by trained research staff prior to any study-specific procedures. Participants may provide consent on the day of approach or after further consideration, according to preference.
Sample Size Rationale
The primary analysis will compare mean change in cDAPSA from baseline to Week 12 between patients initiating 4th/5th-line versus 2nd/3rd-line b/tsDMARD. The non-inferiority margin is set at -5.7 cDAPSA points, based on published estimates of the minimally clinically important difference, and the investigators assume SD = 12.36 for the 12-week change from published data. With one-sided α = 0.05 and 80% power, the required sample size is \~58 per group. Allowing for 10% drop out, this gives 65 per group, for a total of 130 participants across the two primary groups (equal allocation). Patients initiating first-line therapy and those on 6th-line or beyond will also be recruited as descriptive comparative cohorts. To ensure adequate precision for secondary endpoints (including patient-reported outcomes and quality-of-life measures) and to support regression analyses of treatment sequencing, the investigators plan to over-recruit, aiming for approximately 100 patients in each of the four groups (1st line, 2nd/3rd, 4th/5th, and 6th+; ≈400 total). Based on pilot data from Bath, which indicates around 80 patients have been commenced on b/tsDMARD therapy over a year, the investigators anticipate that recruitment from ten sites with a 50% consent rate will allow us to meet our recruitment target over 18 months.
Bias, Confounding, and Data Quality
Given the observational design, several strategies will be implemented to minimise bias. Screening logs will be maintained to evaluate recruitment patterns and potential selection bias. Analyses will adjust for pre-specified confounders, including study site, age, sex, baseline disease activity, disease duration, and comorbidities. Standardised electronic case report forms, validated PROMs, and site training will be used to reduce information bias.
Standardised data collection forms, training of research staff, and use of validated patient-reported outcome measures will minimise variation in data collection across sites. Loss to follow-up will be monitored, and reasons recorded where available. Sensitivity analyses will explore the impact of missing data, including multiple imputation where appropriate.
Statistical Analysis
The primary endpoint is change in cDAPSA score from baseline to Week 12. A non-inferiority margin of -5.7 points has been pre-specified based on published minimally clinically important difference thresholds. Change in cDAPSA will be analysed using analysis of covariance (ANCOVA), adjusting for baseline cDAPSA, age, sex, disease duration, relevant comorbidities, and study centre. A one-sided α = 0.05 will be used. Analyses will be conducted in both intention-to-treat and per-protocol populations.
Secondary endpoints will be analysed using regression models with covariate adjustment consistent with the primary analysis.
Achievement of minimal disease activity (MDA) at Week 12 and composite clinical response (cDAPSA low disease activity plus BSA \<1%) will be analysed using logistic regression. Continuous change in skin involvement (body surface area, BSA) will be analysed using analysis of covariance (ANCOVA), with logistic regression used for categorical skin response thresholds.
Patient-reported outcomes, including health-related quality of life (PsAID-9), physical function (HAQ-DI), and patient global assessment (PGADA), will be analysed using ANCOVA models adjusting for baseline values and predefined covariates.
Treatment persistence will be evaluated using Kaplan-Meier survival analysis and Cox proportional hazards regression. Flare outcomes, as measured by the PsA Flare questionnaire, will be analysed using logistic regression.
Anti-drug antibody (ADA) outcomes will be summarised descriptively, including prevalence, incidence, and titre distribution by therapy line. Exploratory analyses will assess associations between ADA status or titres, circulating drug levels, clinical response, treatment-related adverse events, and treatment persistence using appropriate multivariable models.
Missing data are anticipated due to incomplete follow-up. The primary analysis will assume data are missing at random and will use multiple imputation for continuous and binary Week-12 endpoints, incorporating baseline values and predefined covariates. Sensitivity analyses will include complete-case analyses and conservative assumptions for binary outcomes. For time-to-event endpoints, participants lost to follow-up will be right-censored at the last known treatment date, and event times will not be imputed.
Adults with a confirmed diagnosis of PsA, meeting CASPAR classification criteria, who are initiating a new advanced therapy (b/tsDMARD) as part of routine NHS care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with PsA initiating their first biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine NHS clinical care. Treatment is prescribed by the treating clinician and not assigned by the study.
Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)
Participants with PsA initiating a second or third b/tsDMARD following prior advanced therapy exposure. All treatments are part of routine clinical care.
Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)
Participants with PsA initiating a fourth or fifth b/tsDMARD as part of routine care after multiple prior advanced therapy switches.
Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)
Participants with PsA initiating a sixth or subsequent b/tsDMARD during routine clinical care.
Drug: Biologic or targeted synthetic DMARD (b/tsDMARD)
This is a non-interventional observational study. Participants will receive biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as part of routine NHS clinical care, and no treatment will be assigned by the study. Participants will be categorised into cohorts according to the line of advanced therapy being initiated at study entry (first line, second/third line, fourth/fifth line, and sixth line or beyond). The study will evaluate treatment outcomes, circulating drug levels, and anti-drug antibody (ADA) status across these treatment-line groups. All treatment decisions remain at the discretion of the treating clinician.
Clinical Disease Activity in Psoriatic Arthritis (cDAPSA)
The cDAPSA is the primary outcome and is a validated composite measure of disease activity in PsA. It is calculated as the sum of the tender joint count (0-68 joints), swollen joint count (0-66 joints), patient global assessment of disease activity (0-10 cm visual analogue scale), and patient assessment of arthritis pain (0-10 cm VAS). Unlike the full DAPSA, cDAPSA does not include C-reactive protein. Scores provide a continuous measure of disease activity, with established thresholds to categorise disease states: remission (≤4), low disease activity (\>4-13), moderate disease activity (\>13-27), and high disease activity (\>27).
Time frame: Weeks 0/12
Body Surface Area of Psoriasis (BSA)
In the BSA assessment, the patient's hand (including the palm, fingers, and thumb) will be used as the reference point for measuring how much of their skin is affected by psoriasis, representing roughly 1% of the body's surface. The BSA palm method will be used for the evaluation of BSA affected by psoriasis as follows: * Head and neck=10% (10 palms) * Upper extremities=20% (20 palms) * Trunk=30% (30 palms) * Lower extremities=40% (40 palms) * Total BSA=100%
Time frame: Week 0/12
Minimal Disease Activity (MDA)
Minimal Disease Activity (MDA) is a validated composite outcome used in psoriatic arthritis to define a state of low disease activity across the main clinical domains. A patient is considered to have achieved MDA if they meet at least 5 out of the following 7 criteria: 1. Tender joint count ≤1 2. Swollen joint count ≤1 3. Psoriasis-affected body surface area (BSA) ≤3% 4. Patient pain visual analogue scale (VAS) ≤15 mm 5. Patient global assessment of disease activity VAS ≤20 mm 6. Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤0.5 7. Tender entheseal points ≤1
Time frame: Weeks 0/12
Psoriatic Arthritis Impact of Disease-9 (PsAID-9)
The PsAID-9 is a short, validated tool designed to capture the impact of psoriatic arthritis from the patient's perspective \[14\]. It consists of nine domains that patients rate on a 0-10 numerical rating scale, where higher scores indicate worse status. The domains are: pain, fatigue, skin problems, work/leisure activities, functional capacity, discomfort, sleep disturbance, coping, and anxiety/fear. Each domain is weighted according to its relative importance, and an overall weighted mean score (0-10) is calculated. A score below 4 is generally considered to represent a patient-acceptable symptom state.
Time frame: Weeks 0/4/12/24/52
Health Assessment Questionnaire-Disability Index (HAQ-DI)
The HAQ-DI contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Study participants will be required to indicate the degree of difficulty they experience in each domain in the past week on a 4-point scale that ranges from 0 (without difficulty) to 3 (unable to do). The HAQ-DI score ranges from 0 to 3. A lower HAQ-DI score indicates an improvement in function.
Time frame: Weeks 0/4/12/24/52
Patients' Global Assessment of Disease Activity (PGADA VAS)
The study participant's global assessment of disease activity (PGADA) will be performed using a 100mm visual analog scale (VAS) scale where 0 is "very good, no symptoms" and 100 is "very poor, severe symptoms". The study participant will be asked the following question: "In all the ways in which your psoriasis and arthritis, as a while, affects you, how would you rate the way you felt over the past week?". The study participant will be asked to consider his/her arthritis symptoms and functional capacity in their response to this question.
Time frame: Weeks 0/4/12/24/52
Duration of time on b/tsDMARD
Duration on b/tsDMARD therapy will be defined as the time in weeks from the date of first dose to the date of permanent discontinuation for any reason (including inefficacy, adverse events or patient choice). Patients who remain on therapy at last follow-up will be censored at that date. If there has been any period of time off treatment deemed by the treating physician to be clinically impactful, the patient will be excluded from the study.
Time frame: Weeks 0/4/12/24/52
Patient completed disease flare questionnaire (FLARE)
The PsA Flare Questionnaire is a validated, patient-completed tool designed to capture episodes of disease flare from the patient's perspective. It consists of ten yes/no items covering key disease domains, including: joint pain and swelling, skin psoriasis, impact of activities of daily living, mobility, frustration, depression, tiredness and a change in number or combination of symptoms from PsA. Each "yes" response scores one point, giving a total score from 0 to 10. A threshold of ≥4 has been shown to represent a clinically meaningful flare.
Time frame: Weeks 0/4/12/24/52
Anti-drug antibody (ADA) and non-trough drug levels
ADAs will be measured using standardised, in-house sandwich enzyme-linked immunosorbent assays (ELISA) developed at the University of Bath. These assays are designed to be fully drug-tolerant, allowing detection of ADAs despite the presence of circulating drug, and include assessment of neutralising ADAs, addressing key limitations of many previous immunogenicity studies in PsA. Unlike most previous studies, which have primarily measured total ADAs alone, the investigators will also be able to characterise immunoglobulin isotypes, including IgM, IgE, IgA and IgG subclasses (IgG1-4), providing potential relevance to ADA effector mechanisms.
Time frame: Weeks 0/12
Plan to share: Undecided
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 93 non-industry observational studies under Psoriasis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 119. This study's planned 12 months is below that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal United Hospitals Bath NHS Foundation Trust